CN104525149A - Middle molecule adsorbent for epidemic hemorrhagic fever and preparation method thereof - Google Patents
Middle molecule adsorbent for epidemic hemorrhagic fever and preparation method thereof Download PDFInfo
- Publication number
- CN104525149A CN104525149A CN201410626140.XA CN201410626140A CN104525149A CN 104525149 A CN104525149 A CN 104525149A CN 201410626140 A CN201410626140 A CN 201410626140A CN 104525149 A CN104525149 A CN 104525149A
- Authority
- CN
- China
- Prior art keywords
- parts
- hemorrhagic fever
- middle molecule
- molecule adsorbent
- ethyl cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/48—Sorbents characterised by the starting material used for their preparation
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
The invention discloses a middle molecule adsorbent for epidemic hemorrhagic fever and a preparation method thereof. The middle molecule adsorbent comprises the following raw materials in parts by weight: 40-80 parts of divinyl benzene, 30-60 parts of poly-hydroxyethyl methylacrylate, 40-80 parts of polytetrafluoroethylene, 30-60 parts of ethyl cellulose, 40-80 parts of polyphenyl propylene, 50-70 parts of magnesium oxide, 90-120 parts of calcium oxide and 20-50 parts of monocalcium phosphate. The preparation method comprises the following steps: uniformly mixing the divinyl benzene, the poly-hydroxyethyl methylacrylate, the polytetrafluoroethylene, the ethyl cellulose, the polyphenyl propylene, the magnesium oxide, the calcium oxide and the monocalcium phosphate, reacting the materials for 1-2h under conditions of 130-200 DEG C and 0.6-0.8kPa, adding the ethyl cellulose, carrying out heat treatment, and finally reacting the obtained mixture for 3-8h under conditions of 220-270 DEG C and 27-30kPa. The middle molecule adsorbent is used for treating epidemic hemorrhagic fever. By utilizing the middle molecule adsorbent, middle molecules can be effectively absorbed, and the clearance rate is high.
Description
Technical field
The present invention relates to biological medicine Material Field, particularly relate to a kind of Middle molecule adsorbent for Hemorrhagic fever and preparation method thereof.
Background technology
Hemorrhagic fever is also known as HFRS, and be the disease of natural focus caused by epidemic hemorrhagic fever virus, extensively popular, sb.'s sickness becomes critical, and case fatality rate is high, very harmful.Human beings worldwide's viral hemorrhagic fever has 13 kinds, has harmless according to this sick kidney, is divided into and has kidney to undermine without kidney damage two large classes.HFRS (HFRS) is mainly in China.Before pathogen is unresolved, claim Hemorrhagic fever (EHF) in China, claim KHF (KHF) in Korea, claim hemorrhagic nephroso-nephritis (HNN) in Russia.Due to the establishment of specific serological diagnosis and the solution of pathogen, nineteen eighty-two, the World Health Organization was unified by its called after HFRS.Hemorrhagic fever is the acute infectious disease that virus causes.Cardinal symptom has heating, hemorrhage and kidney damage etc.Infection sources rural area mainly Apodemus agrarius, city is Rattus norvegicus.Route of transmission is determined not yet completely, may be relevant with colonizing in mouse gamasid with it, also can fall ill by the dust sucked through the pollution such as saliva, urine excrement of Apodemus agrarius etc.Epidemic season is April to June (small peak) and October to December (peak).Distribute in crowd at ordinary times.Hemorrhagic fever viruse invades blood of human body, after 1 ~ 2 week incubation period, there is heating and poisoning symptom, then whole body thin vessels and capillary infringement is caused, blood plasma spills from the vascular wall of damage, pachyemia, circulating blood volume reduce, producing hypotensive shock. blood vessel damages further, and each internal organs can be caused hemorrhage.Produce albuminuria, oliguresis and acute renal failure etc. during renal blood vessels infringement, then nephridial tissue reparation, renal tubule are newborn, and renal tubule again absorption function not yet recover, therefore cause diuresis.A series of change is relevant with the immune response of patient above.
Medium molecular substance is one of major toxicity material accumulated in patient with severe symptoms's blood such as Hemorrhagic fever, removes the Middle molecule in blood samples of patients by Middle molecule adsorbent blood perfusion, is the effective ways of alleviating and treating Hemorrhagic fever.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, provide a kind of Middle molecule adsorbent for Hemorrhagic fever and preparation method thereof, the Middle molecule adsorbent for Hemorrhagic fever is effective, and clearance rate is high.
In order to solve the problems of the technologies described above, the present invention by the following technical solutions:
For the Middle molecule adsorbent of Hemorrhagic fever, comprise the raw material of following parts by weight: divinylbenzene 40 ~ 80 parts, poly hydroxy ethyl acrylate 30 ~ 60 parts, polytetrafluoroethylene (PTFE) 40 ~ 80 parts, ethyl cellulose 30 ~ 60 parts, polystyrene 40 ~ 80 parts, 50 ~ 70 parts, magnesia, 90 ~ 120 parts, calcium oxide, calcium dihydrogen phosphate 20 ~ 50 parts.
As to further improvement of the present invention, for the Middle molecule adsorbent of Hemorrhagic fever, comprise the raw material of following parts by weight: divinylbenzene 60 parts, poly hydroxy ethyl acrylate 50 parts, polytetrafluoroethylene (PTFE) 60 parts, ethyl cellulose 40 parts, polystyrene 60 parts, 60 parts, magnesia, 100 parts, calcium oxide, calcium dihydrogen phosphate 30 parts.
As to further improvement of the present invention, magnesian particle diameter is 80 ~ 100 μm.
As to further improvement of the present invention, the particle diameter of calcium oxide is 40 ~ 100 μm.
Present invention also offers a kind of preparation method of the Middle molecule adsorbent for Hemorrhagic fever.
A kind of preparation method of the Middle molecule adsorbent for Hemorrhagic fever, comprise the following steps: divinylbenzene, poly hydroxy ethyl acrylate, polytetrafluoroethylene (PTFE), ethyl cellulose, polystyrene, magnesia, calcium oxide, calcium dihydrogen phosphate mix, 130 ~ 200 DEG C, reaction 1 ~ 2h under 0.6 ~ 0.8kPa condition; Add ethyl cellulose, heat-treat, finally at 220 ~ 270 DEG C, reaction 3 ~ 8h under 27 ~ 30kPa condition.
As to further improvement of the present invention, heat treatment temperature is 400 ~ 800 DEG C, and the time is 20 ~ 40min.
Beneficial effect: the present invention is used for the treatment of Hemorrhagic fever, effectively can adsorb Middle molecule, clearance rate is high, is 63.4 ~ 67.3%, this is because polytetrafluoroethylene (PTFE) can significantly improve the adsorption effect of Middle molecule adsorbent.And Middle molecule adsorbent of the present invention is applied to treatment Hemorrhagic fever good effect, the death rate of Middle molecule adsorbent and blood dialysis therapeutic alliance Hemorrhagic fever obviously reduces.
Detailed description of the invention
Below in conjunction with specific embodiment, the invention will be further described.
embodiment 1
For the Middle molecule adsorbent of Hemorrhagic fever, comprise the raw material of following parts by weight: divinylbenzene 60 parts, poly hydroxy ethyl acrylate 50 parts, polytetrafluoroethylene (PTFE) 60 parts, ethyl cellulose 40 parts, polystyrene 60 parts, 60 parts, magnesia, 100 parts, calcium oxide, calcium dihydrogen phosphate 30 parts.
Magnesian particle diameter is 90 μm.
The particle diameter of calcium oxide is 70 μm.
A kind of preparation method of the Middle molecule adsorbent for Hemorrhagic fever, comprise the following steps: divinylbenzene, poly hydroxy ethyl acrylate, polytetrafluoroethylene (PTFE), ethyl cellulose, polystyrene, magnesia, calcium oxide, calcium dihydrogen phosphate mix, 150 DEG C, react 1.5h under 0.7kPa condition; Add ethyl cellulose, heat-treat, finally 250 DEG C, react 5h under 28kPa condition.
Heat treatment temperature is 600 DEG C, and the time is 30min.
embodiment 2
For the Middle molecule adsorbent of Hemorrhagic fever, comprise the raw material of following parts by weight: divinylbenzene 40 parts, poly hydroxy ethyl acrylate 30 parts, polytetrafluoroethylene (PTFE) 40 parts, ethyl cellulose 30 parts, polystyrene 40 parts, 50 parts, magnesia, 90 parts, calcium oxide, calcium dihydrogen phosphate 20 parts.
Magnesian particle diameter is 80 μm.
The particle diameter of calcium oxide is 40 μm.
A kind of preparation method of the Middle molecule adsorbent for Hemorrhagic fever, comprise the following steps: divinylbenzene, poly hydroxy ethyl acrylate, polytetrafluoroethylene (PTFE), ethyl cellulose, polystyrene, magnesia, calcium oxide, calcium dihydrogen phosphate mix, 130 DEG C, react 1h under 0.6kPa condition; Add ethyl cellulose, heat-treat, finally 220 DEG C, react 3h under 27kPa condition.
Heat treatment temperature is 400 DEG C, and the time is 20min.
embodiment 3
For the Middle molecule adsorbent of Hemorrhagic fever, comprise the raw material of following parts by weight: divinylbenzene 80 parts, poly hydroxy ethyl acrylate 60 parts, polytetrafluoroethylene (PTFE) 80 parts, ethyl cellulose 60 parts, polystyrene 80 parts, 70 parts, magnesia, 120 parts, calcium oxide, calcium dihydrogen phosphate 50 parts.
Magnesian particle diameter is 100 μm.
The particle diameter of calcium oxide is 100 μm.
A kind of preparation method of the Middle molecule adsorbent for Hemorrhagic fever, comprise the following steps: divinylbenzene, poly hydroxy ethyl acrylate, polytetrafluoroethylene (PTFE), ethyl cellulose, polystyrene, magnesia, calcium oxide, calcium dihydrogen phosphate mix, 200 DEG C, react 2h under 0.8kPa condition; Add ethyl cellulose, heat-treat, finally 270 DEG C, react 8h under 30kPa condition.
Heat treatment temperature is 800 DEG C, and the time is 40min.
comparative example 1
Identical with embodiment 1, difference is: do not add polytetrafluoroethylene (PTFE).
performance test
Measure the properties of product of embodiment and comparative example, the results are shown in Table 1.
Table 1
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Comparative example 1 | |
| Middle molecule adsorption rate % | 67.3 | 63.4 | 66.8 | 43.2 |
The Middle molecule adsorbent of embodiment 1 is used for the treatment of the death rate of Hemorrhagic fever.The results are shown in Table 2.
Table 2
Experimental group: the Middle molecule adsorbent of embodiment 1 and blood dialysis therapeutic alliance Hemorrhagic fever, observes the death rate.
Control group: blood dialysis treatment Hemorrhagic fever, observes the death rate.
| Experimental group | 6.8% |
| Control group | 18.3% |
Conclusion: the present invention is used for the treatment of Hemorrhagic fever, effectively can adsorb Middle molecule, clearance rate is high, is 63.4 ~ 67.3%, the clearance rate not adding the Middle molecule adsorbent of polytetrafluoroethylene (PTFE) only 43.2%, illustrates that polytetrafluoroethylene (PTFE) can significantly improve the adsorption effect of Middle molecule adsorbent.And the death rate of Middle molecule adsorbent of the present invention and blood dialysis therapeutic alliance Hemorrhagic fever obviously reduces, illustrate that this Middle molecule adsorbent is applied to treatment Hemorrhagic fever good effect.
Claims (6)
1. for the Middle molecule adsorbent of Hemorrhagic fever, it is characterized in that, comprise the raw material of following parts by weight: divinylbenzene 40 ~ 80 parts, poly hydroxy ethyl acrylate 30 ~ 60 parts, polytetrafluoroethylene (PTFE) 40 ~ 80 parts, ethyl cellulose 30 ~ 60 parts, polystyrene 40 ~ 80 parts, 50 ~ 70 parts, magnesia, 90 ~ 120 parts, calcium oxide, calcium dihydrogen phosphate 20 ~ 50 parts.
2. the Middle molecule adsorbent for Hemorrhagic fever according to claim 1, it is characterized in that, comprise the raw material of following parts by weight: divinylbenzene 60 parts, poly hydroxy ethyl acrylate 50 parts, polytetrafluoroethylene (PTFE) 60 parts, ethyl cellulose 40 parts, polystyrene 60 parts, 60 parts, magnesia, 100 parts, calcium oxide, calcium dihydrogen phosphate 30 parts.
3. the Middle molecule adsorbent for Hemorrhagic fever according to claim 1, is characterized in that, magnesian particle diameter is 80 ~ 100 μm.
4. the Middle molecule adsorbent for Hemorrhagic fever according to claim 1, is characterized in that, the particle diameter of calcium oxide is 40 ~ 100 μm.
5. based on the preparation method of the Middle molecule adsorbent for Hemorrhagic fever according to claim 1, it is characterized in that, comprise the following steps: divinylbenzene, poly hydroxy ethyl acrylate, polytetrafluoroethylene (PTFE), ethyl cellulose, polystyrene, magnesia, calcium oxide, calcium dihydrogen phosphate mix, 130 ~ 200 DEG C, reaction 1 ~ 2h under 0.6 ~ 0.8kPa condition; Add ethyl cellulose, heat-treat, finally at 220 ~ 270 DEG C, reaction 3 ~ 8h under 27 ~ 30kPa condition.
6. the preparation method of the Middle molecule adsorbent for Hemorrhagic fever according to claim 5, is characterized in that, heat treatment temperature is 400 ~ 800 DEG C, and the time is 20 ~ 40min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626140.XA CN104525149B (en) | 2014-11-10 | 2014-11-10 | Middle molecule adsorbent for epidemic hemorrhagic fever and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626140.XA CN104525149B (en) | 2014-11-10 | 2014-11-10 | Middle molecule adsorbent for epidemic hemorrhagic fever and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104525149A true CN104525149A (en) | 2015-04-22 |
| CN104525149B CN104525149B (en) | 2016-11-02 |
Family
ID=52840882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410626140.XA Active CN104525149B (en) | 2014-11-10 | 2014-11-10 | Middle molecule adsorbent for epidemic hemorrhagic fever and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104525149B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111957304A (en) * | 2020-08-19 | 2020-11-20 | 上海金成高分子材料有限公司 | Macroporous adsorption resin for blood perfusion and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004025268A2 (en) * | 2002-09-13 | 2004-03-25 | Carnegie Mellon University | Optical biosensors and methods of use thereof |
| CN101058068A (en) * | 2007-05-31 | 2007-10-24 | 浙江工商大学 | Macroporous adsorption resin special used for separating antibiotic and its preparation method |
| CN101177265A (en) * | 2007-11-13 | 2008-05-14 | 南京大学 | Mesopore spherical activated carbon and preparation method thereof |
| CN101824117A (en) * | 2010-02-04 | 2010-09-08 | 中南大学 | Chelate resin immobilized with dendrimer and preparation method thereof |
| CN102049242A (en) * | 2011-01-08 | 2011-05-11 | 广州康盛生物科技有限公司 | Anion resin for bilirubin absorption and preparation method thereof |
| CN102221585A (en) * | 2010-04-16 | 2011-10-19 | 中国科学院大连化学物理研究所 | Application method of magnesium oxide microsphere in environmental water sample |
| CN102423687A (en) * | 2011-08-08 | 2012-04-25 | 重庆希尔康血液净化器材研发有限公司 | Preparation method of resin carbon for blood purification |
| CN102725008A (en) * | 2009-08-07 | 2012-10-10 | 汉莫堤克股份有限公司 | Device and method for eliminating biologically harmful substances from bodily fluids |
-
2014
- 2014-11-10 CN CN201410626140.XA patent/CN104525149B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004025268A2 (en) * | 2002-09-13 | 2004-03-25 | Carnegie Mellon University | Optical biosensors and methods of use thereof |
| CN101058068A (en) * | 2007-05-31 | 2007-10-24 | 浙江工商大学 | Macroporous adsorption resin special used for separating antibiotic and its preparation method |
| CN101177265A (en) * | 2007-11-13 | 2008-05-14 | 南京大学 | Mesopore spherical activated carbon and preparation method thereof |
| CN102725008A (en) * | 2009-08-07 | 2012-10-10 | 汉莫堤克股份有限公司 | Device and method for eliminating biologically harmful substances from bodily fluids |
| CN101824117A (en) * | 2010-02-04 | 2010-09-08 | 中南大学 | Chelate resin immobilized with dendrimer and preparation method thereof |
| CN102221585A (en) * | 2010-04-16 | 2011-10-19 | 中国科学院大连化学物理研究所 | Application method of magnesium oxide microsphere in environmental water sample |
| CN102049242A (en) * | 2011-01-08 | 2011-05-11 | 广州康盛生物科技有限公司 | Anion resin for bilirubin absorption and preparation method thereof |
| CN102423687A (en) * | 2011-08-08 | 2012-04-25 | 重庆希尔康血液净化器材研发有限公司 | Preparation method of resin carbon for blood purification |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111957304A (en) * | 2020-08-19 | 2020-11-20 | 上海金成高分子材料有限公司 | Macroporous adsorption resin for blood perfusion and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104525149B (en) | 2016-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2516403C (en) | Method for removal of viruses from blood by lectin affinity hemodialysis | |
| Zandi et al. | Extract of Scutellaria baicalensis inhibits dengue virus replication | |
| Wang et al. | Sequential blood purification therapy for critical patients with hyperlipidemic severe acute pancreatitis | |
| CN100348268C (en) | Method for preparing carbonized resin DNA immunoadsorbent | |
| JPS62242628A (en) | Protein a-silica immunoadsorbent and manufacture | |
| Asgharpour et al. | COVID-19 and kidney disease: update on epidemiology, clinical manifestations, pathophysiology and management. | |
| CN104525149A (en) | Middle molecule adsorbent for epidemic hemorrhagic fever and preparation method thereof | |
| CN104689804A (en) | Styrene resin adsorbent of new structure for removing AIDS (Acquired Immune Deficiency Syndrome) virus molecules in blood | |
| CN102552369B (en) | Lon icera japonica Thunb leaf extractive serving as anti-porcine reproductive and respiratory syndrome viral agent | |
| CN102190725A (en) | Hand-foot-and-mouth disease resistant human immunoglobulin, and preparation and using methods and application thereof | |
| Habas et al. | Common complications of hemodialysis: A clinical review | |
| Kim et al. | Improvement of virus safety of an antihemophilc factor IX by virus filtration process | |
| Raina et al. | Blood filters in children with COVID‐19 and acute kidney injury: A review | |
| CN106267410A (en) | HIV (human immunodeficiency virus) infection cell separator | |
| WO1999064071A1 (en) | A method for preparing a carbonized resin dna immunoadsorbent | |
| WO2002083157A1 (en) | Blood group-free human blood plasma and the preparation method thereof | |
| CN101024824A (en) | A method for the inactivation and removal of dengue virus from biological samples | |
| CN101397339A (en) | Method for removing/inactivating virus in glucoprotein | |
| Joshi et al. | Antiviral effects of quillaja Saponaria extracts against human noroviral surrogates | |
| CN108578693B (en) | For treating the photochemical method for preparation of the autologous plasma inactivated vaccine of AIDS | |
| Focosi et al. | High-dose convalescent plasma for treatment of severe COVID-19 | |
| CN104624170B (en) | Adsorbent for treating gram bacterial infection and blood perfusion device | |
| CN103223197A (en) | Combined medical apparatus device for toxemia blood purifying | |
| CN102526493A (en) | Medicine for resisting tuberculosis and preparation method thereof | |
| Kim et al. | Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Qiu Caijun Inventor before: Pan Lingen Inventor before: Qiu Dongcheng Inventor before: Liu Lefeng |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160905 Address after: 312400 Zhejiang city of Shaoxing province Shengzhou City Zhijie Lake Yan North Street No. 108 commercial city building 6 room 613 Applicant after: Zhejiang Yicheng industrial product design Co., Ltd. Address before: Wuzhong District town Suzhou city Jiangsu province 215101 gold Jinchang Road No. 360 Applicant before: Suzhou Vivotide Biotechnologies Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171213 Address after: 225500 south side of Tongyang West Road, Jiangyan Economic Development Zone, Taizhou City, Jiangsu Province Patentee after: Taizhou Qida coating Auxiliaries Co., Ltd. Address before: 312400 Zhejiang city of Shaoxing province Shengzhou City Zhijie Lake Yan North Street No. 108 commercial city building 6 room 613 Patentee before: Zhejiang Yicheng industrial product design Co., Ltd. |